PharmaFocus Today – Page 392 – media

Boston Scientific’s ACURATE neo2 prosthetic Aortic Valve performs well in study

Boston Scientific’s ACURATE neo2 prosthetic aortic valve system witnessed an “a high procedural success rate and a low rate of paravalvular aortic regurgitation (leakage of blood near the valve),” after being implanted for a month in a clinical study. The company is publicizing the findings of the study before it is made available in the market. It was observed that 97% of individuals showed no or little paravalvular aortic regurgitation and the positioning of the implant was quick and successful without any significant complications in the same percentage of patients registered in the ACURATE neo2 CE-Mark Study. Moreover, the all-cause mortality rate in the study was found to be 3.3% and a disabling stroke was reported in 1.7% of the patients. Severe Paravalvular leak (PVL) was reported in none while mild or lesser PVL was noted in about 97% of patients and 3% reported moderate PVL. Data pertaining to the implanting ...
- Source: drugdu
- 367
- September 13, 2018
Baxter’s new Actifuse Flow bone graft alternative gets FDA nod.

Actifuse Flow, Baxter International’s new synthetic bone graft surrogate from its osteobiologics surgery series, wins FDA approval for implementation in orthopedic surgeries. In order to reach tine bony cracks and gaps of the skeletal structure, the new bone graft alternative is designed to reach these exact cranny locations. It is delivered via a syringe already containing it to speed-up bone growth. No preparatory procedure or mixing is needed to use this bone graft substitute and it maintains its fluid consistency during the surgery. The surgical products manufacturer’s Actifuse Bone Graft Alternative constituting Actifuse Flow implements the silicate-substituted technology for bone formation via raised levels of silicon. It becomes an ideal candidate for minimally invasive surgical procedures as the syringe facilitates the start and stop of flow to deliver the precise amount of substance. This also enables it to compact small done deformities as well as the intricate disorder of bone ...
- Source: drugdu
- 1,066
- September 13, 2018
Notable quantity of carcinogenic chemicals absorbed by lungs in an e-cigarette use.

The Desert Research Institute (DRI) and the University of Nevada, Reno researchers’ new pilot study reveals that a vaping (e-cigarette use) episode exposes the user’s respiratory pathway to a considerable quantity of carcinogens like formaldehyde, which alarms everyone about the dangers of vaping. “Until now, the only research on the respiratory uptake of aldehydes during smoking has been done on conventional cigarette users,” said Vera Samburova, Ph.D., associate research professor in DRI’s Division of Atmospheric Sciences and lead author of the study. “Little is known about this process for e-cigarette use, and understanding the unique risks vaping poses to users is critical in determining toxicological significance.” The breath of 12 e-cigarette consumers before and post vaping were tested for measurement of existence of harmful chemicals. Samburova and her associate Khlystov designed a way to measure this during their study. The method enabled them to measure the quantity of aldehydes in ...
- Source: drugdu
- 1,355
- September 12, 2018
FDA approves Masimo’s Tiny Breathing Sensor for Paediatric patients in U.S.

The RAS-45 acoustic respiration sensor, developed by Masimo, to function along with the Rainbow Acoustic Monitoring (RAM), was approved by the FDA for use in neonates and infant patients. A minimum weight of 22pounds/10 kgs of the baby was required earlier to be eligible for use of RAM sensors. This requirement is no longer necessary for the new sanction that enables a convenient monitoring of the rate of respiration in very young pediatric patients. This is possible because the maximum respiration rate in the sensor has been raised to 120 breaths per minute with an excellent precision between +/- breath every minute. The sensor can be stuck on to the child and it is fitted with a microphone mimicking device that spots respiration sounds from other background sounds. Its clarity enables pediatricians to listen to the breathing of the infant as if he/she is listening via a stethoscope. The sensor ...
- Source: drugdu
- 1,133
- September 12, 2018
Brain Atrophy slowed by Multiple Sclerosis Drug

Ibudilast retarded brain atrophy in 255 advancing multiple scleroses (MS) patients more than a placebo in a National Institute of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) funded the brain imaging clinical trial. 28 clinical locations were studied for 96 weeks to evaluate the decline in brain atrophy progress. MRI scans were done on the patients’ brains half-yearly. Varied analysis techniques were used as scales to measure the variations in brain alterations seen in the MRI films among the two groups. Brain atrophy was observed in both the groups but the ibudilast group demonstrated the slower rate of shrinkage of the brain. The brain shrunk by 2.5ml more over two years in the group on placebo. NINDS director Walter Koroshetz said, “These findings provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options.” ...
- Source: drugdu
- 835
- September 12, 2018
Hospital stay reduced to half with Danish endocarditis plan

A Danish, multicenter, randomized POET trial revealed that after declared clinically stable on taking intravenous antibiotics in a hospital for one to two weeks, left-sided endocarditis patients could be sent home with a prescription of antibiotics to be taken orally to complete the rest of the treatment. “Shifting to oral antibiotic treatment in stabilized patients with endocarditis was as effective and safe as continued intravenous antibiotic treatment and was given during half the antibiotic treatment period. These novel findings may have a significant impact on future clinical practice for the management of patients who are stable,” Henning Bundgård, MD, said at the annual congress of the European Society of Cardiology. Guiding principles from the ESC and American Heart Association/American College of Cardiology suggest 6 weeks of intravenous antibiotics for the management of infective endocarditis. This reduces the stay in the hospital to half resulting in lowering of the expenses borne by ...
- Source: drugdu
- 1,282
- September 11, 2018
Retention in de-addiction therapy increased on administration of medicines.

Medications like buprenorphine, naltrexone, or methadone when added to treatment of opioid use disorder (OUD) youths, resulted in longer adherence to in-care regimen. However, very few receive the medicines, reveals a retrospective cohort study. The study on 4,837 OUD youths between the age 13-22 years including 2,752 females observed that only 1 out of 4 youths and 1 out of 21 adolescents received medication, as reported by Scott E. Hadland, MD, MPH, MS, of Grayken Center for Addiction and Department of Pediatrics, Boston Medical Center, and coinvestigators. The results brought greater attention to the need for better management of OUD in young adults and increase their adherence to treatment, noted Dr. Hadland and co-authors in JAMA Pediatrics. “As deaths from overdose increase among U.S. youths, it is vital that clinicians, researchers, and policy makers ensure that access to evidence-based OUD medications for young people remains a national priority,” they said. The ...
- Source: drugdu
- 977
- September 11, 2018
Crazy cat lady syndrome might also treat cancer

We might have come across many people who are usually obsessed with cats. But at times, this obsession can turn into madness. Where does this madness arise from? There is a research link between the cat parasite named Toxoplasma gondii and the psychiatric disorders like bipolar disorder and schizophrenia. House cats are considered as the primary hosts of Toxoplasma gondii. But according to a study published in Psychological Medicine in 2017, it was reported that just having the cats doesn’t increase the risk of psychosis. It’s the cat parasite that causes psychosis. Later, a research team from Dartmouth College’s Geisel School of Medicine NH, were trying to find the parasite’s immune power against cancer tumors, with the ultimate goal of making a cancer vaccine. Researchers have known that T. gondii infection strongly induces a Th1 immune response, which can increase the cancer survival rates. David J. Bzik, PhD, the lead ...
- Source: drugdu
- 764
- September 11, 2018
Global Recall – Hypertension drugs contain wrong drug

A global recall for blood pressure drugs has been issued by Accord Healthcare, since they contain a heart failure drug. Oral consumption of 12.5 mg hydrochlorothiazide tablets is used to treat high blood pressure. Recently during the export of one lot of 100-count bottles, it was discovered that the lot contains spironolactone tablets. The company believed that no other lot was involved in this confusion. Hence, Accord Healthcare recalled the lot since spironolactone pills can immediately alter the potassium levels, which leads to life threatening issues. Though spironolactone is used to treat liver cirrhosis and heart failure, it should be consumed only under doctor’s recommendation. The US- Food and Drug Administration said that it was a pharmacist, who first alerted Accord Healthcare to the issue. Later Accord Healthcare said that it had not received any reports of injuries due to this issue. The hydrochlorothiazide pills are peach or light orange ...
- Source: drugdu
- 220
- September 11, 2018
Wearable chronic pain reliever app – Quell 2.0

Nearly millions of people throughout the world are living with chronic pain in one form or the other. With the rise of opioids in the epidemic level, there arises a rise in search for new treatment measures. The wearables company named NeuroMetrix had redesigned their device named Quell for an easier and convenient utilization. The modified Quell 2.0 app has taken the FDA approved nerve stimulation technology to the next level, which is supposed to be the latest breakthrough for chronic pain treatment. The Quell 2.0 device is smarter, 50% smaller and 20% more powerful. The new Quell 2.0 app is available online at www.QuellRelief.com. Quell 2.0 app is integrated with a neurostimulation microchip which includes all the features of Quell device. It easily adapts to changes in body position and automatically starts the therapy in switch-on mode. This app is user-friendly with a varied automation feature like start and stop, ...
- Source: drugdu
- 391
- September 11, 2018

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.